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Introduction 
 
Testosterone, a steroid hormone from the 
androgen group, is among the oldest marketed 
drugs, with a long record of safe and effective 
use for its principal indication of testosterone 
replacement in androgen deficient men. 
However, over recent decades, testosterone and 
other androgens have increasingly been used as 
drugs of abuse, complete with an illicit market 
and their own folklore. 
 
Objective 
 
The aim of this study was to perform a 
comparative chemical quality evaluation of 
topical testosterone formulations, both obtained 
from a hospital pharmacy and via the internet. 
 
Experimental 
 
 Formulations 
 
Six different formulations were analyzed. 
Formulations 1 to 4 were authorized 
pharmaceuticals obtained from a hospital 
pharmacy, while formulations 5 and 6 were 
purchased via the internet. 
 
 Liquid chromatography 
 
Assay of testosterone was done by validated 
HPLC-UV. The HPLC apparatus consisted of a 
Waters Alliance 2695 separations module and a 
Waters 2996 photodiode array detector (all 
Waters, USA). LC separations were performed 
using a Lichrospher 100 RP18 (125 mm × 4 mm, 
5 µm particle size) column (Merck, Darmstadt, 
Germany) thermostated at 30°C, with a mobile 
phase consisting of a mixture of (A) 0.1% m/V 
formic acid in water, and (B) 0.1% m/V formic 
acid in acetonitrile. The flow rate was set at 1.0 
mL/min. UV detection was done at 254 nm. 
Related impurities were determined by LC-
DAD/ESI ion trap mass spectrometry. The LC-
DAD/MS apparatus consisted of a SN4000 
 
interface, a SCM1000 degasser, a P1000XR 
pump, an AS3000 autosampler and a LCQ 
Classic ion trap mass spectrometer (all Thermo, 
USA) equipped with a Waters 2996 photodiode 
array detector (Waters, USA). The method used 
was based upon the assay for related impurities 
of testosterone described in the European 
Pharmacopeia 5.0 (Ph.Eur). LC separations were 
performed using a Lichrospher 100 RP18 (125 
mm × 4 mm, 5 µm particle size) column (Merck, 
Darmstadt, Germany) thermostated at 40°C, with 
a mobile phase consisting of a mixture of (A) 
H2O/methanol (45:55, V/V), and (B) pure 
methanol. The flow rate was set at 1.0 mL/min. 
 
 Dissolution tests 
 
Biopharmaceutical properties were evaluated by 
an in-house developed ‘paddle over disk’ 
dissolution test (see Figure 1) using  several 
physiologically relevant media: phosphate 
buffered saline (PBS), PBS + 0.5% bovine serum 
albumin (BSA), PBS + 0.5% hydroxy-propyl-
beta-cyclodextrine (HPBCD), simulated sweat, 
simulated sweat + 0.5% HPBCD, simulated body 
fluid and simulated body fluid + 5% BSA. The 
membrane used to cover the formulations was a 
SpectraPor® dialysis membrane with a MWCO 
of 12-14000 Da. 
 
Figure 1: Paddle over disk dissolution test. 
 
 
 Results and discussion 
 
 Assay of testosterone 
 
Results for the assay of testosterone by HPLC-
UV are given in Table 1. The testosterone 
content of formulations 1 to 5 was within 
specifications (95-105% of the label claim), 
while formulation 6 did not contain any 
testosterone at all. 
Table 1 
Formulation Origin Assay (% label claim) 
1 Hospital 102.82 (± 0.98) 
2 Hospital 101.38 (± 0.95) 
3 Hospital 102.61 (± 2.20) 
4 Hospital 102.66 (± 3.37) 
5 Internet 102.18 (± 0.18) 
6 Internet Not detected(1) 
(1) Detection limit = 0.15 µg/g formulation. 
 Related impurities 
 
Reporting threshold (RT) for individual 
impurities was set at 0.05%. The identification 
and quantification threshold, defined as 
acceptance specification limit, was set at 0.20%, 
with the exception of the epimeric testosterone 
impurity (limit set at 0.50%), based upon the Ph. 
Eur. limits. 
Results are given in Table 2. Based upon the 
relative retention times, the UV-spectrum and 
the mass spectrum, 2 of the impurities were 
identified: the first one was due to epimerization 
of testosterone and the second impurity consisted 
of oxidized forms of testosterone. 
 
Table 2 
Formu-
lation 
n(1) 
Impurities (%) 
Oxidised 
testosterone 
Epimeric 
testosterone 
Total peak 
area 
1 3 - - 0.11 
2 3 0.07 0.28 0.41 
3 7 0.05 0.41 1.01 
4 8 0.12 0.28 1.45 → 0.98 
5 4 0.30 0.55 0.99 
6 - - - - 
(1) n = number of impurity peaks above RT. 
Formulation 4 was a patch and hence 
testosterone unrelated HPLC peaks due to patch 
extraction were observed, totalling 1.45%. The 
major peak of 0.47% was unambiguously 
identified by LC-DAD/MS
n
 as a patch 
compound, resulting in a maximal total peak area 
related to testosterone of 0.98%. 
 
 Biopharmaceutical properties 
 
The topical formulations were brought into an 
in-house developed extraction cell and a ‘paddle-
over-disk’ dissolution test was performed. 
Typical curves obtained are shown in Figure 2. 
 
 
 
Figure 2: Dissolution curves obtained for formulations 1 – 3 
using PBS + 0.5% BSA as medium. 
 
Different dissolution profiles were obtained for 
the formulations, depending on the media used 
as well. The clinical relevance of these different 
biopharmaceutical behaviours remains to be 
elucidated. 
 
Conclusion 
 
While the majority of the formulations conforms 
the acceptance specifications defined, the two 
internet obtained products were not in 
compliance. Formulation 6 was presented as a 
pharmaceutical product, but did not contain 
testosterone at all. A too high impurity content 
was found in formulation 5 for the two identified 
impurities. The dissolution tests are promising as 
a valuable discriminating biopharmaceutical 
characterisation. 
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